Literature DB >> 22065358

Risk of venous thromboembolism with oral contraceptives.

Susan Solymoss1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22065358      PMCID： PMC3255133          DOI： 10.1503/cmaj.111614

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study.

Authors:  Naomi Gronich; Idit Lavi; Gad Rennert
Journal:  CMAJ       Date:  2011-11-07       Impact factor: 8.262

2.  Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.

Authors:  Elizabeth F W van Vlijmen; Nic J G M Veeger; Saskia Middeldorp; Karly Hamulyák; Martin H Prins; Harry R Büller; Karina Meijer
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

3.  Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study.

Authors:  John A Heit; Catie E Kobbervig; Andra H James; Tanya M Petterson; Kent R Bailey; L Joseph Melton
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

4.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.

Authors:  Jürgen C Dinger; Lothar A J Heinemann; Dörthe Kühl-Habich
Journal:  Contraception       Date:  2007-02-23       Impact factor: 3.375

5.  Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis.

Authors:  S Hennessy; J A Berlin; J L Kinman; D J Margolis; S M Marcus; B L Strom
Journal:  Contraception       Date:  2001-08       Impact factor: 3.375

6.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 7.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

8.  Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.

Authors:  Susan S Jick; Rohini K Hernandez
Journal:  BMJ       Date:  2011-04-21

9.  Hormonal contraception and risk of venous thromboembolism: national follow-up study.

Authors:  Øjvind Lidegaard; Ellen Løkkegaard; Anne Louise Svendsen; Carsten Agger
Journal:  BMJ       Date:  2009-08-13
  9 in total
  1 in total

1.  Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.

Authors:  Jan de Jong; Anna Mitselos; Wojciech Jurczak; Raul Cordoba; Carlos Panizo; Tomasz Wrobel; Monika Dlugosz-Danecka; James Jiao; Juthamas Sukbuntherng; Daniele Ouellet; Peter Hellemans
Journal:  Pharmacol Res Perspect       Date:  2020-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.